Cargando…

Assessment of the Relation Between SNP in MxA Gene and the Responsiveness of Egyptian HCV Genotype 4 Patients to Pegylated Interferon and Ribavirin Treatment

BACKGROUND: Pegylated interferon (PegIFN) is used in the treatment of chronic hepatitis C virus (HCV) patients especially in resource limited countries. Treatment with PegIFN stimulates the expression of a number of host genes encoding enzymes with antiviral activities, including myxovirus resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassany, Mohamed, Gamal, Amany, Zaki, Nashwa, Eysa, Basem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412542/ https://www.ncbi.nlm.nih.gov/pubmed/28496530 http://dx.doi.org/10.14740/gr810w

Ejemplares similares

Ribavirin Enhances IFN-α Signalling and MxA Expression: A Novel Immune Modulation Mechanism during Treatment of HCV
por: Stevenson, Nigel J., et al.
Publicado: (2011)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Polymorphisms of the MxA and MxB genes are associated with biochemical indices and viral subtypes in Yunnan HCV patients
por: He, Mengzhu, et al.
Publicado: (2023)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Vaccinia virus and Cowpox virus are not susceptible to the interferon-induced antiviral protein MxA
por: Lorenzo, María M., et al.
Publicado: (2017)

The antiviral effect of interferon-beta against SARS-Coronavirus is not mediated by MxA protein
por: Spiegel, Martin, et al.
Publicado: (2004)

Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population
por: Hamano, Emi, et al.
Publicado: (2005)

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
por: Ahmed, Mohammed Mahmound, et al.
Publicado: (2013)

Corrigendum: Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population
por: Zang, Feng, et al.
Publicado: (2019)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Detection of new biallelic polymorphisms in the human MxA gene
por: Duc, Tam Tran Thi, et al.
Publicado: (2012)

MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients
por: Serana, Federico, et al.
Publicado: (2014)

Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients
por: Matas, Elisabet, et al.
Publicado: (2014)

Interferon-α-induced cytoplasmic MxA structures in hepatoma Huh7 and primary endothelial cells
por: Davis, Deodate, et al.
Publicado: (2018)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome
por: Maria, Naomi I, et al.
Publicado: (2014)

Rapid Reversible Osmoregulation of Cytoplasmic Biomolecular Condensates of Human Interferon-α-Induced Antiviral MxA GTPase
por: Sehgal, Pravin B., et al.
Publicado: (2022)

The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis
por: Khairy, Marwa, et al.
Publicado: (2013)

Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection
por: Aizawa, Yoshio, et al.
Publicado: (2013)

Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
por: Hu, Zhongjie, et al.
Publicado: (2015)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients
por: Aparicio, Ester, et al.
Publicado: (2010)

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
por: Domagalski, K., et al.
Publicado: (2013)

IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C
por: Estrabaud, Emilie, et al.
Publicado: (2015)

HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b
por: Fan, Zhijuan, et al.
Publicado: (2019)

Conformational dynamics of dynamin-like MxA revealed by single-molecule FRET
por: Chen, Yang, et al.
Publicado: (2017)

Association of functional polymorphisms in the MxA gene with susceptibility to enterovirus 71 infection
por: Zhang, Xiaoai, et al.
Publicado: (2013)

Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin
por: Bukowska-Ośko, Iwona, et al.
Publicado: (2015)

Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
por: Emara, Mohamed H, et al.
Publicado: (2010)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Lack of Induction by Rhinoviruses of Systemic Type I Interferon Production or Enhanced MxA Protein Expression During the Common Cold
por: Mäkelä, M. J., et al.
Publicado: (1999)

Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3
por: Niederau, Claus, et al.
Publicado: (2014)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
por: Chen, Zhi-wei, et al.
Publicado: (2017)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

The Curious Case of Type I IFN and MxA: Tipping the Immune Balance in AIDS
por: Furuya, Andrea Kinga Marias, et al.
Publicado: (2014)

Blood MxA protein as a marker for respiratory virus infections in young children
por: Toivonen, Laura, et al.
Publicado: (2015)

MxA for differentiating viral and bacterial infections in adults: a prospective, exploratory study
por: Metz, Matthäus, et al.
Publicado: (2023)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
por: Vogel, M, et al.
Publicado: (2010)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kvrjfek73c0hrgall8gjijc3l4